Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Depression: Overview

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Depressive Disorders: Etiology

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...

Depressive Disorders: MDD and Dysthymia

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Brexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease: Clinical Perspectives.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026

Same author

Effect of Frailty on Depression among Patients with Late-life Depression: A Test of Anger, Anxiety, and Resilience as Mediators.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2024

Same author

The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2024

Same author

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2023

Same author

Investigating the effectiveness of a smart mental health intervention (inMind) for stress reduction during pharmacological treatment for mild to moderate major depressive disorders: Study protocol for a randomized control trial.

Frontiers in psychiatry·2023

Same author

Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2023

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Atypical depression: a comprehensive review.

Chi-Un Pae¹, Haresh Tharwani, David M Marks

¹Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, South Korea. pae@catholic.ac.kr

|December 5, 2009

Summary

Atypical depression remains difficult to diagnose, but mood reactivity is a key feature. Monoamine oxidase inhibitors (MAOIs) show superior efficacy over tricyclic antidepressants (TCAs) for this subtype.

More Related Videos

A New Method for Inducing a Depression-Like Behavior in Rats

A New Method for Inducing a Depression-Like Behavior in Rats

Published on: February 22, 2018

The Forced Swim Test as a Model of Depressive-like Behavior

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

Related Experiment Videos

Last Updated: Jun 18, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

A New Method for Inducing a Depression-Like Behavior in Rats

A New Method for Inducing a Depression-Like Behavior in Rats

Published on: February 22, 2018

The Forced Swim Test as a Model of Depressive-like Behavior

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

Area of Science:

Psychiatry
Neuroscience
Pharmacology

Background:

Atypical depression characteristics remain ambiguous despite extensive research.
Evidence supports atypical depression as a distinct subtype with unique hormonal, neurological, and psychological profiles.
Differential treatment response further validates atypical depression as a clinically relevant subtype.

Purpose of the Study:

To review the evolution of diagnostic criteria for atypical depression, focusing on mood reactivity.
To examine the evidence for drug treatments in atypical depression, comparing older and newer agents.
To identify future research directions for diagnostic refinement and treatment clarification.

Main Methods:

Literature review of research on atypical depression characteristics and diagnostic criteria.
Systematic review of studies on the pharmacological treatment of atypical depression.
Analysis of comparative efficacy and tolerability data for various antidepressant classes.

Main Results:

Mood reactivity is identified as the cardinal diagnostic feature of atypical depression.
Monoamine oxidase inhibitors (MAOIs) demonstrate superior efficacy compared to tricyclic antidepressants (TCAs).
Newer antidepressants, including selective serotonin reuptuptake inhibitors (SSRIs), show comparable efficacy and better tolerability than MAOIs and TCAs in limited studies.

Conclusions:

Diagnostic reliability and validity of atypical depression require further refinement.
Atypical depression shows a preferential response to MAOIs over TCAs.
More randomized controlled trials are needed to establish the efficacy of newer antidepressants for atypical depression.